Background--Delayed cerebral infarction (DCI) is a major cause of morbidities after aneurysmal subarachnoid hemorrhage (SAH) and typically starts at day 4 to 7 after initial hemorrhage. MicroRNAs (miRNAs) play an important role in posttranscriptional gene expression control, and distinctive patterns of circulating miRNA changes have been identified for some diseases. We aimed to investigate miRNAs that characterize SAH patients with DCI compared with those without DCI.
A neurysmal subarachnoid hemorrhage (SAH) accounts for about 3% to 5% of stroke and is an important cause of stroke in young populations, causing significant socioeconomic burden worldwide. 1 Up to two thirds of SAH patients experience cognitive impairment and impaired quality of life and may not be able to return to their previous work. [2] [3] [4] [5] [6] [7] [8] Delayed cerebral infarction (DCI) occurs in up to 44% of SAH patients and typically starts at day 4 to 7 after the initial hemorrhage. [9] [10] [11] DCI is a well-established and relevant clinical surrogate marker for neurological outcome after SAH. 12 Numerous factors including age, initial neurological impairment, intraventricular hemorrhage, SAH load, and aneurysm size are reported to be associated with the development of DCI. [13] [14] [15] [16] MicroRNAs (miRNAs) are a family of small (19-23 base pairs), noncoding, and deeply conserved RNA molecules that regulate target gene expression at a posttranscriptional level by inhibiting mRNA translation 17 or destabilizing mRNA molecules. 18 There are 1881 miRNAs in human genomes, 296 of which are currently annotated as high confidence, according to miRBase 21.0. 19 Circulating miRNAs have been demonstrated to be promising diagnostic or prognostic biomarkers for cerebrovascular conditions such as myocardial infarction, 20 atherosclerotic diseases, 21 stroke, 22 cerebral infarction, 23 hypertension, 24 intracranial aneurysms, [25] [26] [27] [28] and SAH. 29, 30 In the current study, we aimed to investigate miRNAs that characterized SAH patients with DCI compared with those without DCI.
Methods Patient Recruitment and Sample Collection
The study was approved by the Joint NTEC-CUHK (New Territories East Cluster-Chinese University of Hong Kong) Clinical Research Ethics Committee, and written informed consent was obtained from all participants or their next of kins. Circulating miRNAs were collected from healthy controls (n=20), SAH patients with DCI (n=20) at day 7 after SAH, and SAH patients without DCI (n=20) at day 7 after SAH. SAH patients were recruited from Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China, between 2012 and 2013. Ruptured cerebral aneurysms were diagnosed by computer tomography angiography. For SAH patients, the healthy controls (n=20) were recruited from the family members of SAH patients with the no major medical problem (including no smoking history and hypertension). Participant characteristics are shown in Table 1 .
Delayed Cerebral Infarction
DCI is defined as a new cerebral infarction identified on computed tomography after exclusion of procedure-related infarctions. 3, 12 Procedure-related infarction was defined as new hypodensity appearing on the posttreatment computed tomography at 12 to 24 hours after aneurysm treatment. All recruited patients had delayed computed tomography of the brain at 2 to 3 weeks after presentation available for assessment. The diagnoses of DCI were made by consensus of 2 neuroradiologists.
Quantitative Polymerase Chain Reaction
Peripheral blood samples were obtained using EDTA tubes with standard procedures. Samples were placed on ice immediately and centrifuged at 1000g for 15 minutes at 4°C. Plasma fraction was aliquoted and stored at À80°C. RNA isolation and quantitative real-time polymerase chain reaction were performed, as described previously. 29 Briefly, serum was prepared by adding 20% wt/vol CaCl 2 (Sigma-Aldrich) into the plasma samples at a ratio of 1:100, followed by clotting overnight and centrifugation. Total RNA was isolated from pooled serum samples using the miRNeasy Serum/Plasma Kit following the manufacturer's instructions (Qiagen). The quantity of the extracted RNA was determined using a Nanodrop 2000 UV-Vis spectrophotometer (Thermo Scientific). The results were analyzed with the Applied Biosystems SDS software for Ct values and melting curve analyses. Of the 99 possible deregulated miRNAs associated with SAH, 29 we selected the top 20 differentially regulated miRNAs between SAH patients with and without DCI; the top 8 miRNAs between SAH patients with DCI and healthy controls (2 overlapped); and miR-132-3p and miR-324-3p, the 2 previously reported circulating miRNAs in SAH patients 29 from a total of 28 unique miRNAs for expression analysis. Table S1 is the list of quantitative polymerase chain reaction primers for miRNA expression profiling used in this study.
Statistical Analyses
Heat maps with hierarchical clustering and principal component analysis (PCA) were computed and visualized using the functions pHeatmap and prcomp, respectively, from the stats package for R version 3.0.1 (R Foundation for Statistical Computing). The R package pROC was used to plot and visualize receiver operating characteristic (ROC) curves to compute the area under the curve (AUC) and confidence intervals to evaluate the performance of the miRNA-based classifier. 31 Different R packages and functions were used to construct the 4 classification models to identify the miRNAbased classifiers that could differentiate SAH patients with or without DCI after SAH-the linear support vector machine (R package e1071, function svm, kernel="linear"), nonlinear support vector machine (R package e1071, function svm, kernel="radial"), linear discriminant analysis (R package MASS, function lda), and logistic regression (R package stats, function glm, family="binomial")-as previously described. 32 The R package glmnet was used to fit the LASSO (least absolute shrinkage and selection operator) regression model via penalized maximum likelihood to define the miRNA-based classifier. 33 The value k=0.07765104 based on crossvalidation, and t tests were used to compute the P value (Tables 1 and 2 We next performed quantitative polymerase chain reaction array analyses to quantify the expression levels of the 28 SAH-associated miRNAs ( Figure 1A ) and used PCA for pattern recognition to evaluate the distance connectivity of the 2 SAH subtypes ( Figure 1B ). PCA generated 2 distinct clusters with minimal overlap of the 2 SAH subtypes, highlighting the possibility of characterizing the disease subtypes using a miRNA combination.
miRNAs That Characterized SAH With DCI
Given the distinctive pattern of miRNA expression profile between the 2 SAH subtypes, we initially evaluated the performance of individual miRNAs to characterize SAH patients with and without DCI using ROC analysis. 34 Based on the sensitivity (true-positive rate) and specificity (false-positive rate) at varied threshold levels, the ROC analysis allowed us to select possibly optimal models for DCI discrimination. We plotted the ROC curves for individual miRNAs from a total of 28 miRNAs according to their quantitative polymerase chain reaction-measured expression levels in the SAH groups with DCI and without DCI. The results are shown in Table 2 . The AUCs of 8 miRNAs can achieve >85% (P<0.0005), and 4 of them-miR-4532, miR-4793, miR-1290, and miR-421-are >90%. For miR-1290, the AUC, specificity, and sensitivity were 95.3% (95% CI 0.897-1), 0.900, and 0.850, respectively, at a cutoff level of 8.653.
We postulated that a combination of miRNAs would show characteristics for SAH with versus without DCI. We examined each miRNA combination of the 28 SAH-associated miRNAs, based on their sensitivity, specificity, and accuracy, using the 4 different classifier algorithms: linear support vector machine, nonlinear support vector machine, linear discriminant analysis, and logistic regression. The results are shown in Figure 2 . All 3 readouts improved while increasing the number of miRNAs contained in each classifier. We next performed the LASSO regression analysis involving penalizing the absolute size of the regression coefficients to determine the accuracy using a combination of miRNAs to distinguish SAH with and without DCI ( Figure 3A) . The results are shown in Figure 3B . ROC analysis indicated that the AUC achieved 100% (95% CI 1-1, P<0.0001) using 4 miRNAs, namely, miR-4463, miR-4532, miR-4793, and miR-1290, according to the LASSO regression model and the ROC analysis using the following formula: ln(Y/1ÀY)=À4.29759355+ miR-446390.16589606+miR-453290.43352951+miR-47939 0.09569081+miR-129090.2602013. PCA analysis indicated that the 4-miRNA combination could produce 2 nonoverlapping clusters to unambiguously differentiate SAH with and without DCI.
Interestingly, the 4 miRNAs were strongly repressed in SAH blood samples with DCI but activated in the non-DCI samples compared with healthy controls (Figure 4) . The biphasic expressions of these 4 miRNAs in the SAH patients with or without DCI also provided discrimination with an AUC >80% by ROC analyses to differentiate the SAH patients with or without DCI from healthy controls with AUCs of 99.3% (95% CI 0.977-1, P<0.0001) and 82.0% (95% CI 0.685-0.955, P<0.0005), respectively. The results supported the diseasespecific nature of the 4 miRNAs.
Discussion
In this study, both the heat map and PCA analysis suggested that a combination of miRNAs could characterize SAH patients with DCI from those without DCI (Figure 1) . We demonstrated that a number of miRNAs could offer good to excellent discriminatory power between SAH with and without DCI ( Table 2) . LASSO regression analysis and PCA analysis further demonstrated that a 4-miRNA combination (miR-4463, miR-4532, miR-4793, and miR-1290) could produce 2 nonoverlapping clusters to unambiguously differentiate SAH with and without DCI, with an AUC of 100% (95% CI 1-1, P<0.0001) (Figure 3 ). In addition, the classifier can also distinguish the healthy controls from each SAH subtype with or without DCI (Figure 4) , highlighting its disease specificity.
Recently, studies of miRNAs in serum and cerebrospinal fluid identified biomarkers associated with occurrence of SAH, including miR-92a, let-7b, miR-204-5p, miR-223-3p, miR-337-5p, miR-451a, miR-489, miR-508-3p, miR-514-3p, miR-516-5p, Figure 2 . Four classification models, namely, linear support vector machine (L-SVM), nonlinear support vector machine (non-L-SVM), linear discriminant analysis (LDA), and logistic regression (LR) models, were applied to construct microRNA (miRNA) classifiers. The performance of the miRNA-based classifiers was determined by leave-one-out cross-validation. The x-axis denotes the number of miRNAs contained in the classifier, whereas the y-axis indicates the performance of the classifiers including sensitivity (green circle), specificity (blue square), and accuracy (red triangle). In each group with the same miRNA number, only the classifier displaying the best performance is presented.
miR-548, miR-599, miR-937, miR-1224-3p and miR-1301. 29, 35, 36 Our previous genomewide serum miRNA expression profiling also suggested that miR-132-3p and miR-324-3p
could be potential biomarkers for SAH. 29, 35, 36 Styllis and others investigated cerebrospinal fluid miRNAs in 10 SAH patients with and 10 without cerebral vasospasm and identified miR- 27a-3p, miR-516a-5p, miR-566, and miR-1197 as potential biomarkers for cerebral vasospasm but not DCI. 36 The identification of miRNAs associated with DCI after SAH has been understudied, hindering understanding and development of therapeutic strategies for DCI after SAH.
Given that the downstream targets and functional specificities of the 4 miRNAs (miR-4463, miR-4532, miR-4793 and miR-1290) are uncharacterized, we performed gene-centric analysis to identify their common and unique potential targets using 3 algorithms: TargetScan, miRanda, and PITA. Considerable overlaps of their downstream targets were shared by these 4 miRNAs, inferring that these miRNAs may act on common regulatory pathways mediated by their shared targets for the development of DCI after SAH ( Figure 5 ). KEGG (Kyoto Encyclopedia of Genes and Genomes) and gene ontology analyses also consistently revealed that the targets of these 4 miRNAs associated with multiple developmental pathways including Wnt signaling pathway, hedgehog and oxytocin signaling pathways. These pathways are broadly involved in neurogenesis and nervous system development, suggesting that these 4 miRNAs may function as causative factors in DCI pathology associated with SAH (Table S2) .
The 4 novel miRNAs-miR-4463, miR-4532, miR-4793, and miR-1290-have not been associated with SAH pathology. miR-4532 has been associated with breast cancer cell chemotherapy resistance. 37 has been shown to serve as a biomarker for a common female reproductive disease called polycystic ovary syndrome and arteriosclerosis obliterans. 42, 43 Our current study had several limitations. First, our SAHassociated miRNA pools were obtained from patients at day 7 after SAH, which is a commonly reported time point for etiological study of DCI. Time-course expression profiling of serum miRNAs in SAH patients at multiple time points could investigate stage/time-specific miRNAs for SAH with or without DCI in future. Second, the current study did not investigate the pathophysiological roles of these miRNAs in DCI after SAH and propose therapeutic targets. Third, the sample size was small, and subgroup analyses such as admission neurological grade and the mode of aneurysm treatment were not performed. In addition, the sample size did not allow meaningful matched group analyses. Fourth, 28 miRNAs were selected to find the important miRNAs involved to guide further mechanistic study to find therapeutic targets. Fifth, there could be a limitation in diagnosing DCI with computed tomography hypodensity, as magnetic resonance imaging was not routinely performed in our patients. Sixth, validation with another patient cohort would be warranted to confirm our findings. Seventh, cerebrospinal fluid samples were not collected for miRNA analysis and should be considered in future study.
Our work was important as it provides an understanding of the characteristics of circulating miRNAs associated with DCI after SAH. The 4 miRNAs might play distinct roles in DCI after SAH. Further investigations into their roles might bring new therapeutic targets for DCI after SAH. Future time-course studies of miRNAs might also identify SAH patients at risk of subsequent DCI development for stringent monitoring in neurocritical care units and timely treatment.
Conclusions
We found a 4-miRNA combination (miR-4532, miR-4463, miR-1290, and miR-4793) that characterized SAH patients with DCI. The findings could guide future mechanistic study to develop therapeutic targets. 
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